ロード中...
Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
Since their discovery as drivers of proliferation, cyclin-dependent kinases (CDKs) have been considered therapeutic targets. Small molecule inhibitors of CDK4/6 are used and tested in clinical trials to treat multiple cancer types. Despite their clinical importance, little is known about how CDK4/6...
保存先:
| 出版年: | Nat Commun |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8184839/ https://ncbi.nlm.nih.gov/pubmed/34099663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23612-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|